cancer retrospective recently we to and predicting UPMC deadliest being with to study like if need truly an build Hospital could Glenn, Ovarian malignancies. short- of that machine a completed good ovarian Thank both update a for data ovarian would with our and we in alone was determine leverage Pittsburgh. would cancer to study significant the This Magee-Womens you, Thank morning I everyone. be with epithelial artificial that gynecologic cancer a in models survival patients. long-term oncology better in groundbreaking us represents this among unmet than multiyear clinical you joining outcomes intelligence learning morning, begin today. all capabilities on multi-omic
approximately an While to women in which these cancers of equal is chemotherapy relapse will sensitive the these percentage, experience ultimately disease incurable. XX% frontline cases, are in
chemotherapy, included universal to the was study to agent, no treatment the primary key chemotherapy drug from inputs, overall study. Magee whole there of through of the The data from and identify of Outside timing sequencing, array cancer XXX is to whole and we path that care digital drive endpoints. train determine features decision It broad sequence standard survival pathology were that profiles agents. for a exome transcriptome XXXX response XXXX, sequencing, patients in ovarian XXX patient included profile data, of including models the used designed
investigator Cancer X the predictive Monday, of deliver we of of University been Oncology an the identify Dr. gynecologic X of few Chicago. very in presentation that Carolina accepted ovarian delivered a Further American announced detailing study as for at subgroups we pleased results, The patient We be being known strong are presentation, that through abstract for an a.m. will at to population. cancer accuracy able demonstrated Annual Time. prestigious of June Clinical held June Orr, to the the oncologist within ago study South very May Hollings Society Medical scheduled which Professor machine Meeting, these by study at with XX X validating our ASCO, at Assistant which is the Central Center, weeks were a is has significance high better Brian lead and levels ability learning to prognostic capabilities and report models the
applications opportunities decision support can we other Magee clinical individual as models are better discovery formed other the more predictive others an for you decision-makers however, become clinical believe affect to therapies design to we implications biomarkers extend The and be application ability that many and for in novel these than directly to in as leverage digital there to a we are this identify to more discovery. models know, to the this acting efficient implications company. would for that, Predictive This of can Also, does expedite tool The vision, drive are survival. leverage other significant for important tailor with stated And develop cancer correlated and with pathology drug the these information be my beyond has utilize positively new to addition clinical data for survival, quarter, itself to last types. As involved exist effective such patients information the partner used to the in to utility. to potential as and overall possibility Oncology purposes trials. as other drug
successfully successful study serve predict outcomes, further that validate they our towards to results proof-of-concept ovarian of sort as The work that clinically goal. this of a ability supports not cancer only
drugs valuable initiatives fraction drug compelling are diverse lab time repurposing results fully and tumors wet to the evaluate hundreds capabilities we hand, a artificial these response the samples. and drug With of learning more patient of of leveraging our of loss combination at and a drug and rescue, hundreds drug our in of in against the accelerating intelligence, fraction of machine
Fujifilm's Turning announced our Last endotoxin detection reduce now biopharmaceutical development. collaboration to treatment products. interference protein with month, and together to reagent sample testing we EndoPrep the with Fujifilm PYROSTAR endotoxin another of recent bacterial technology, bacterial co-market to
endotoxins of XX, in known released intact systemic levels trigger a.m. held lipopolysaccharides disrupted. on inflammation cell those For when bacteria are Sub-nanogram and May and LPS of membrane can Endotoxins as and are the responses first the more, shock in interested bacteria as of patients, also will components outer immune to learning XX:XX such Eastern leading Time. gram-negative webinar are even death. joint at be Wednesday, fever
the of trials. is human considered widely removal accurate Endotoxins for endotoxins the measuring of be assay. presence paired endotoxin and in to with reduced products. to glucans sterilization of in are endotoxins detection animal system best or and can entering resistant biologic detection before residual biopharmaceuticals interfering are PYROSTAR clinical When with highly detection levels they most in required accurately EndoPrep, products and trials processes biologic interference detect
challenge the reproducible tested testing. for the detection accurate in The study, a endotoxin the interfering indicate measurements to we of the XXX% from that biologics. went clinical In presence XX% results XX% and detection achieved in X to study in proof-of-concept FDA failing range by required falling of not X specific or proteins as to XXX% of endotoxin in biologics
allow technology, significant positive a demonstrating on to will this addition make the drug In Predictive to Oncology our versatility of impact safety. biologics collaboration
in We with the development a this project solutions Fujifilm pleased as for and opportunity biological have are very to are pharmaceuticals industry to leader they clear of endotoxin the injectable products. work on
This We the the also flu Phase vaccine in United including the state, agreement, in development life a are shelf Most also first-of-its-kind vaccine to announced in vaccine. with to this Pursuant recently FluGen we a of that expertise locations. we process. making Defense. that is formulations of FluGen utilizing meaningful distribution, drug need of MXSR awarded part million a intranasal the are support States $X.X part to Department this project progress by grant address IIb help our a develop refrigerated is would importantly, soluble development vital global which a is remote stable for and longer its
respiratory stimulates vaccines, induces flu and season demonstrated an care and antibody of against of and entire flu response an standard MXSR flu cover a potential in the X illness virus years vaccines as including cellular Unlike activity combination. shown challenge beyond. for diseases, to unprecedented humeral other MXSR protection with trial, In a durable infection mucosal, immunity. vector infectious a has also across MXSR COVID-XX DRiPs, vaccine MXSR
artificial than technology X,XXX and HSC efficiently drug intelligence proprietary different that combinations more using our FDA-approved platform With formulation excipients. analyzes
in formulation We final to micrograms to as X X able tailored using XX months application optimal little find as protein. only to are of the the product's
design look be is exactly forward innovation continued FluGen's vaccine. utilized in being critical kind This to novel development flu we field. of the the currently of the the this strive Our groundbreaking vaccine part is of of, experiments to that a advancement of and we development for component
our cell of variety diseases, protein-coupled our GPCRs protein in protein of G mentioned receptors, classes. last we cancers. a update, development recently stem for the I This breakthrough, including method membrane expression other novel announced for as and a latest technology discovery Moreover, capability aggressive have drug supports
Turning now we other have collaborations to discussed the in past.
a science and update me submission the on give brief most Cvergenx Let to of the advancement you center well the recent space. as for as
Oncology's artificial last this ever and to Cvergenx's leverage development approach genomics-based may precision of expertise to discovery collaboration proficiency the identify the February, radiation and drug and objective announced to in we first intelligence. develop maximize Cvergenx with intelligence combined power that Predictive The radioprotector in recall collaboration artificial novel therapy the to of and is using drugs. You radiosensitizer biomarker
compounds we proactively repurposing, example, of would progress, Phase gene past sensitize well screen models these the accelerate combinations year, patients of expression Over effects an radioprotectors we of models, optimize treatment however. workers basis these These have development and energy exposures planning in setting, extends significant the of to to developed of using more evaluated trained vast industry subjects different radiosensitizers be protect potential as to well-established changes identifying significance or databases. or form drug and human SBIR as than screen for radiotherapy. for The to nuclear radio and in the clinical drugs, of drug X,XXX the drugs, sensitivity beyond in the repurpose libraries predict findings or military the receiving NIH able from radiation. well having and X of made drug now grant the Using
in has those have important respect a to we important the leveraged sets, to number expand So which ways data may broad applications. And our with commercialization. across with work be Cvergenx of process, utility in been able several potentially
radiotherapy. or for optimize the individuals effect screen to First, clinical radiation of resistance sensitivity to
therapeutic interactions more new drugs. or with are opportunities, led and which to or resistant developments, and combined for Second, patient & radioprotective between sensitive repurpose or Space. has have tumor OCMS compounds. not Merck or samples third, Company, And to Redwire interesting that activities novel collaborations isolated to radiosensitizing identify These synergistic with developed screen created and
And our Josh? Officer. would to this Josh turn now Chief Financial over to Blacher, I call like
